Fatih Toptan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Fatih Toptan has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Ali Fuat Erdem
Department of Anesthesiology and Reanimation, Faculty of Medicine, Sakarya University, Sakarya, Turkiye
1 shared publication - İbRahim Kara
Department of Cardiovascular Surgery, Sakarya University Faculty of Medicine, Sakarya, Türkiye
1 shared publication - Kezban Özmen Süner
Department of Intensive Care, Sakarya University Training and Research Hospital, Sakarya, Türkiye
1 shared publication - Mehmet Gökhan Küçük
Department of Anesthesiology and Reanimation, Faculty of Medicine, Sakarya University, Sakarya, Turkiye
1 shared publication - Mustafa Tarık Ağaç
Department of Cardiology, Ahi Evren Cardiovascular and Thoracic Surgery Training and Research Hospital, Trabzon, Turkey
1 shared publication - Salih Salihi
Department of Cardiovascular Surgery, Medicine Faculty, Sakarya University, Sakarya, Turkey
1 shared publication
Latest Publications
- Open Access
- 24 September 2026
- Published by Turkish Society of Intensive Care in Turkish Journal of Intensive Care
- Vol. 24 (3) , 216-225
Use of bivalirudin in patients during veno-venous extracorporeal membrane oxygenation: a case series
Objective: This study aimed to evaluate the use of bivalirudin as an alternative to conventional anticoagulant therapy with heparin in patients requiring venovenous extracorporeal membrane oxygenation (V-V ECMO) support for Acute Respiratory Distress Syndrome (ARDS), with a focus on dose titration, therapeutic range monitoring, complications, and clinical outcomes. Materials and Methods: This retrospective case series included six patients who received V-V ECMO support and systemic anticoagulation with bivalirudin between August 2021 and April 2022 at Sakarya University Training and Research Hospital due to a diagnosis of ARDS. Activated clotting time (ACT), activated partial thromboplastin time (aPTT), daily bivalirudin infusion doses, ECMO-related complications, and clinical outcomes were retrospectively analyzed. Results: Bivalirudin infusion doses ranged between 0.01 and 0.2 mg/kg/h across all patients. ACT values were maintained within the target range in all cases, while aPTT values remained below target in four patients. Hemorrhagic complications were observed in two patients, while thrombotic events occurred in another two. In one patient, bivalirudin infusion was discontinued due to the development of acute kidney injury. Of the six patients, two were discharged, while four died during follow-up. Conclusion: Bivalirudin appears to be a safe and effective alternative anticoagulant agent for patients undergoing V-V ECMO. However, individualized and meticulous anticoagulation monitoring is essential, particularly in the context of renal dysfunction, the strengths and limitations of aPTT and ACT monitoring, and the delicate balance between hemorrhagic and thrombotic risks.
- 24 September 2026
- Published by Turkish Society of Intensive Care in Turkish Journal of Intensive Care
- Vol. 24 (3) , 216-225
Open AccessUse of bivalirudin in patients during veno-venous extracorporeal membrane oxygenation: a case series
Objective: This study aimed to evaluate the use of bivalirudin as an alternative to conventional anticoagulant therapy with heparin in patients requiring venovenous extracorporeal membrane oxygenation (V-V ECMO) support for Acute Respiratory Distress Syndrome (ARDS), with a focus on dose titration, therapeutic range monitoring, complications, and clinical outcomes. Materials and Methods: This retrospective case series included six patients who received V-V ECMO support and systemic anticoagulation with bivalirudin between August 2021 and April 2022 at Sakarya University Training and Research Hospital due to a diagnosis of ARDS. Activated clotting time (ACT), activated partial thromboplastin time (aPTT), daily bivalirudin infusion doses, ECMO-related complications, and clinical outcomes were retrospectively analyzed. Results: Bivalirudin infusion doses ranged between 0.01 and 0.2 mg/kg/h across all patients. ACT values were maintained within the target range in all cases, while aPTT values remained below target in four patients. Hemorrhagic complications were observed in two patients, while thrombotic events occurred in another two. In one patient, bivalirudin infusion was discontinued due to the development of acute kidney injury. Of the six patients, two were discharged, while four died during follow-up. Conclusion: Bivalirudin appears to be a safe and effective alternative anticoagulant agent for patients undergoing V-V ECMO. However, individualized and meticulous anticoagulation monitoring is essential, particularly in the context of renal dysfunction, the strengths and limitations of aPTT and ACT monitoring, and the delicate balance between hemorrhagic and thrombotic risks.
- Open Access
- 1 July 2025
- Published by Galenos Yayinevi in Turkish Journal of Thoracic and Cardiovascular Surgery
- Vol. 33 (3) , 397-400
Use of an atrial septal defect occluder for the closure of an ascending aorta pseudoaneurysm after coronary artery bypass grafting
An aortic pseudoaneurysm is a rare, but serious condition which can result in life-threatening complications. It is usually caused by previous cardiac surgery, trauma, or infection. Due to the high likelihood of rupture with primary surgical intervention, endovascular closure may be performed as the standard of care in eligible cases. In this article, we present a case of a huge aortic pseudoaneurysm with a wide neck which could safely be closed using an atrial septal occluder.
- 1 July 2025
- Published by Galenos Yayinevi in Turkish Journal of Thoracic and Cardiovascular Surgery
- Vol. 33 (3) , 397-400
Open AccessUse of an atrial septal defect occluder for the closure of an ascending aorta pseudoaneurysm after coronary artery bypass grafting
An aortic pseudoaneurysm is a rare, but serious condition which can result in life-threatening complications. It is usually caused by previous cardiac surgery, trauma, or infection. Due to the high likelihood of rupture with primary surgical intervention, endovascular closure may be performed as the standard of care in eligible cases. In this article, we present a case of a huge aortic pseudoaneurysm with a wide neck which could safely be closed using an atrial septal occluder.